breast cancer - HER2-positive | |
la/mBC - HER2 positive - 1st Line (L1) | |
pertuzumab based treatment | |
pertuzumab plus trastuzumab | PERTAIN |
pertuzumab plus trastuzumab plus docetaxel | CLEOPATRA PUFFIN |
Study type:
delta: difference in rate or median (if available)
- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy -